Prevalence and impact of endocrine disorders in advanced metastatic cancer patients undergoing cancer-directed therapy: A prospective observational study.
Gaurav KarnaAmit SehrawatSaurabh KarnaRavi KantDeepak SundriyalSummi KarnDipesh JhaPublished in: Cancer reports (Hoboken, N.J.) (2024)
Our study highlights the importance of considering endocrine disorders in advanced metastatic cancer patients undergoing therapy. The prevalence of diabetes and thyroid dysfunction increased during cancer-directed therapy, particularly in females. Careful monitoring and timely intervention are essential to improve the quality of life for these patients. Further research is warranted to explore the long-term effects of cancer-directed therapy on endocrine health and develop tailored management strategies for this vulnerable population.
Keyphrases
- papillary thyroid
- patients undergoing
- squamous cell
- small cell lung cancer
- squamous cell carcinoma
- healthcare
- cardiovascular disease
- type diabetes
- risk factors
- randomized controlled trial
- lymph node metastasis
- skeletal muscle
- newly diagnosed
- ejection fraction
- stem cells
- insulin resistance
- mesenchymal stem cells
- social media
- patient reported outcomes
- glycemic control
- peritoneal dialysis